Key Takeaways
- • KKR has agreed to acquire 100% equity stake in Medicover India (operating as Sahrudaya Health Care Private Limited) for approximately €1.2 billion ($1.4 billion USD equivalent), with closing expected in Q4 2026 subject to regulatory approvals.
- • Medicover India operates 24 hospitals with approximately 4,800 beds and 11,400 employees as of June 30, 2026, positioning it as one of India's leading multi-specialty healthcare providers.
- • AZB & Partners served as legal counsel to KKR on the transaction, while McDermott Will & Schulte advised Medicover and its minority shareholders on the sale.
- • The transaction aligns with Medicover's strategic shift to accelerate investment in its core European markets while strengthening its financial position through divestiture of its India operations.
- • The deal represents KKR's continued expansion into the Indian healthcare sector and reflects the firm's broader strategy of acquiring scale-intensive, assets in high-growth emerging markets.
Summary
KKR has agreed to acquire Medicover's entire India hospital business for €1.2 billion, marking a significant transaction in the South Asian healthcare sector. The deal encompasses a 100% equity stake in Medicover India, legally operating under the entity name Sahrudaya Health Care Private Limited. The acquisition includes both Medicover's direct equity holdings and equity interests held by minority shareholders, consolidating full ownership under KKR's investment umbrella. The transaction is subject to customary closing conditions and regulatory approvals, with an expected close date in the fourth quarter of 2026.
Medicover India operates a substantial healthcare footprint across the subcontinent. As of June 30, 2026, the business comprised 24 hospitals with approximately 4,800 beds and employed around 11,400 staff members, establishing it as one of India's leading multi-specialty healthcare providers. This asset base provides KKR with immediate operational scale and an established market presence in a high-growth healthcare market.
The transaction reflects divergent strategic priorities between the buyer and seller. For Medicover, the Swedish healthcare provider views the divestiture as an opportunity to refocus capital and management attention on its core European operations while simultaneously strengthening its balance sheet. For KKR, the acquisition represents a continuation of the firm's healthcare sector investment thesis, particularly in emerging markets where demographic trends and rising incomes drive healthcare demand growth.
Legal representation underscored the transaction's complexity. AZB & Partners advised KKR on the acquisition, while McDermott Will & Schulte represented Medicover and its minority shareholders on the sale. McDermott's transaction team was led by partner Fatema Orjela and counsel Zoe Woodhouse, both specializing in private equity and M&A work, alongside associates Arjun Sehgal and Raees Khan. The involvement of specialized cross-border counsel reflects the regulatory and structural complexities inherent in large-scale healthcare transactions spanning Swedish-listed parent company, Indian operations, and U.S. private equity buyer.
Medicover India operates a substantial healthcare footprint across the subcontinent. As of June 30, 2026, the business comprised 24 hospitals with approximately 4,800 beds and employed around 11,400 staff members, establishing it as one of India's leading multi-specialty healthcare providers. This asset base provides KKR with immediate operational scale and an established market presence in a high-growth healthcare market.
The transaction reflects divergent strategic priorities between the buyer and seller. For Medicover, the Swedish healthcare provider views the divestiture as an opportunity to refocus capital and management attention on its core European operations while simultaneously strengthening its balance sheet. For KKR, the acquisition represents a continuation of the firm's healthcare sector investment thesis, particularly in emerging markets where demographic trends and rising incomes drive healthcare demand growth.
Legal representation underscored the transaction's complexity. AZB & Partners advised KKR on the acquisition, while McDermott Will & Schulte represented Medicover and its minority shareholders on the sale. McDermott's transaction team was led by partner Fatema Orjela and counsel Zoe Woodhouse, both specializing in private equity and M&A work, alongside associates Arjun Sehgal and Raees Khan. The involvement of specialized cross-border counsel reflects the regulatory and structural complexities inherent in large-scale healthcare transactions spanning Swedish-listed parent company, Indian operations, and U.S. private equity buyer.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.